These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 3441327)

  • 21. Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer.
    Pons F; Herranz R; Garcia A; Vidal-Sicart S; Conill C; Grau JJ; Alcover J; Fuster D; Setoain J
    Eur J Nucl Med; 1997 Oct; 24(10):1210-4. PubMed ID: 9323260
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The efficacy of therapy using 89Sr-strontium chloride in 200 patients with bone metastases of a prostatic cancer].
    Haesner M; Buchali K; Pink V; Lips H
    Nuklearmedizin; 1992 Mar; 31(2):48-52. PubMed ID: 1373485
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitation of biochemical markers of bone resorption following strontium-89-chloride therapy for metastatic prostatic carcinoma.
    Papatheofanis FJ
    J Nucl Med; 1997 Aug; 38(8):1175-9. PubMed ID: 9255144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical experience with strontium-89 in prostatic and breast cancer patients.
    Robinson RG; Preston DF; Baxter KG; Dusing RW; Spicer JA
    Semin Oncol; 1993 Jun; 20(3 Suppl 2):44-8. PubMed ID: 8503027
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autopsy of a cadaver containing strontium-89-chloride.
    Schraml FV; Parr LF; Ghurani S; Silverman ED
    J Nucl Med; 1997 Mar; 38(3):380-2. PubMed ID: 9074523
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Question of the month--January 1995. What is the optimal dose of 89Sr for bone pain palliation?
    Khader Z
    Nucl Med Commun; 1995 Apr; 16(4):306. PubMed ID: 7542759
    [No Abstract]   [Full Text] [Related]  

  • 27. Radiation treatment of prostate bone metastases and the biological considerations.
    Bagshaw MA; Kaplan ID; Valdagni R; Cox RS
    Adv Exp Med Biol; 1992; 324():255-68. PubMed ID: 1283500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Influence of 89Sr on the cell immune function in patients with multiple bone metastases].
    Wu YG; Ma QL; Liu GF
    Hunan Yi Ke Da Xue Xue Bao; 2002 Jun; 27(3):277-8. PubMed ID: 12575316
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Radioactive substances (32P and 89Sr) in the treatment of pain in bone metastases].
    Flamm J; Burkert S
    Z Urol Nephrol; 1981 Nov; 74(11):801-6. PubMed ID: 6172913
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Kinetics of radiostrontium].
    Firusian N
    Nucl Med (Stuttg); 1974 Aug; 13(2):127-38. PubMed ID: 4438080
    [No Abstract]   [Full Text] [Related]  

  • 31. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone.
    Lewington VJ; McEwan AJ; Ackery DM; Bayly RJ; Keeling DH; Macleod PM; Porter AT; Zivanovic MA
    Eur J Cancer; 1991; 27(8):954-8. PubMed ID: 1716935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Strontium-89 chloride for pain palliation in prostatic skeletal malignancy.
    Laing AH; Ackery DM; Bayly RJ; Buchanan RB; Lewington VJ; McEwan AJ; Macleod PM; Zivanovic MA
    Br J Radiol; 1991 Sep; 64(765):816-22. PubMed ID: 1717094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Painful bone metastases in hormone-refractory prostate cancer: economic costs of strontium-89 and/or external radiotherapy.
    Malmberg I; Persson U; Ask A; Tennvall J; Abrahamsson PA
    Urology; 1997 Nov; 50(5):747-53. PubMed ID: 9372886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [2 years of experience with 89Sr therapy of multiple bone metastases (author's transl)].
    Correns HJ; Mitterlechner E; Buchali K; Schnorr D; Seidel C; Mebel M
    Radiobiol Radiother (Berl); 1979 Jun; 20(3):360-2. PubMed ID: 515396
    [No Abstract]   [Full Text] [Related]  

  • 35. Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial.
    Porter AT; McEwan AJ
    Semin Oncol; 1993 Jun; 20(3 Suppl 2):38-43. PubMed ID: 7684865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bone pain palliation with 85Sr therapy.
    Giammarile F; Mognetti T; Blondet C; Desuzinges C; Chauvot P
    J Nucl Med; 1999 Apr; 40(4):585-90. PubMed ID: 10210217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Internal strontium-89 radiotherapy for malignant bony metastasis].
    Lou C; Zhang D; Yu L
    Zhonghua Zhong Liu Za Zhi; 2001 Nov; 23(6):507-9. PubMed ID: 11859724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment of symptomatic bone metastases of prostatic carcinoma using strontium chloride (Sr-89)].
    Dormia E; Mantovani F; Minervini S; Malagola G; Castellani R; Dormia G; Gonnella G; Mazza L; Luongo P; Bertana F
    Arch Ital Urol Androl; 1993 Apr; 65(2):161-6. PubMed ID: 8330061
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disseminated intravascular coagulation in a patient with metastatic prostate cancer: fatal outcome following strontium-89 therapy.
    Leong C; McKenzie MR; Coupland DB; Gascoyne RD
    J Nucl Med; 1994 Oct; 35(10):1662-4. PubMed ID: 7931669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Strontium-89 for bone metastases from prostate cancer: an update].
    Zhao WW; Xie P; Deng HF
    Zhonghua Nan Ke Xue; 2010 Mar; 16(3):269-72. PubMed ID: 20369560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.